Artículos de revistas
All-trans Retinoic Acid With Daunorubicin Or Idarubicin For Risk-adapted Treatment Of Acute Promyelocytic Leukaemia: A Matched-pair Analysis Of The Pethema Lpa-2005 And Ic-apl Studies
Registro en:
All-trans Retinoic Acid With Daunorubicin Or Idarubicin For Risk-adapted Treatment Of Acute Promyelocytic Leukaemia: A Matched-pair Analysis Of The Pethema Lpa-2005 And Ic-apl Studies. Springer, v. 94, p. 1347-1356 AUG-2015.
0939-5555
WOS:000357279200011
10.1007/s00277-015-2393-0
Autor
Sanz
Miguel A.; Montesinos
Pau; Kim
Haesook T.; Ruiz-Argueelles
Guillermo J.; Undurraga
Maria S.; Uriarte
Maria R.; Martinez
Lem; Jacomo
Rafael H.; Gutierrez-Aguirre
Homero; Melo
Raul A. M.; Bittencourt
Rosane; Pasquini
Ricardo; Pagnano
Katia; Fagundes
Evandro M.; Vellenga
Edo; Holowiecka
Alexandra; Gonzalez-Huerta
Ana J.; Fernandez
Pascual; De la Serna
Javier; Brunet
Salut; De Lisa
Elena; Gonzalez-Campos
Jose; Ribera
Jose M.; Krsnik
Isabel; Ganser
Arnold; Berliner
Nancy; Ribeiro
Raul C.; Lo-Coco
Francesco; Lowenberg
Bob; Rego
Eduardo M.
Institución
Resumen
Front-line treatment of acute promyelocytic leukaemia (APL) consists of all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy. In this setting, a comparison of idarubicin and daunorubicin has never been carried out. Two similar clinical trials using ATRA and chemotherapy for newly diagnosed APL were compared using matched-pair analysis. One was conducted by the PETHEMA/HOVON group with idarubicin and the other by the International Consortium on APL (IC-APL) using daunorubicin. Three hundred and fifty patients from the PETHEMA/HOVON cohort were matched with 175 patients in the IC-APL cohort, adjusting for the significantly unbalanced presenting features of the two entire cohorts. Complete remission (CR) rate was significantly higher in the PETHEMA/HOVON (94 %) than in the IC-APL cohort (85 %) (P = 0.002). The distribution of causes of induction failure and the time to achieve CR were similar in both cohorts. Patients who achieved CR had comparable cumulative incidence of relapse and disease-free survival rates, but lower overall and event-free survivals were observed in the IC-APL cohort, which was mainly due to a higher death rate during induction therapy. A higher death rate during consolidation therapy was also observed in the IC-APL. These results show that daunorubicin and idarubicin have similar antileukaemic efficacy in terms of primary resistance, molecular persistence, as well as molecular and haematological relapse rates when combined with ATRA in treatment of APL. However, a higher toxic death rate during induction and consolidation therapy was observed in the IC-APL cohort. This trial was registered at as #NCT00408278 [ClinicalTrials.gov]. 94 8
1347 1356 Instituto de Salud Carlos III [RD12/0036/014] European Regional Development Fund [RD12/0036/014] American Society of Hematology Fondazione Umberto Veronesi Roche South Arabia Fundacao de Apoio a Pesquisa do Estado de Sao Paulo [1998/14247-6] Fundacion Mexicana para la Salud St. Jude Children's Research Hospital